medalliance selution

... which will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe. MedAlliance's unique DEB technology involves MicroReservoirs which contain a ...

Jump, Chairman and CEO of MedAlliance. SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in ...

...//mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg View original content: https://www.prnewswire.com/ae/news - releases/medalliance - selution - slr - receives - coronary - fda - ide - - ...

... we are beyond proud to further our legacy of innovation and market disruption with MedAlliance and the first MicroReservoir sirolimus drug - eluting balloon, SELUTION SLR." "I am excited to report ...

...- - An 82 - year - old Taiwanese man has become the first patient to be enrolled in the initial Erectile Dysfunction (ED) randomized clinical trial (RCT) involving SELUTION SLR™, MedAlliance's ...

GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ - - The first US patient has been enrolled in the FDA SELUTION4BTK (Below - the - Knee) clinical trial evaluating SELUTION SLR™, MedAlliance's novel sirolimus - eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient ...

Med Alliance SA Logo: https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg Photo: https://mma.prnewswire.com/media/1875120/MedAlliance_SELUTION.jpg

"This is a great achievement and a major milestone for MedAlliance." SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of ...

Based on the early promising data following the use of SELUTION SLR in treatment of BTK disease, MedAlliance has moved forward with the design of the SELUTION4BTK RCT to further investigate the ...